29 The randomized, double-blind study enrolled 1,864 participants with a mean baseline A1C of 8.3% and BMI of 32.5
M.McLeanC.ByeN.BeartP
Fiori JL, Shin YK, Kim W, et al
These medications are powerful tools, but they are not a replacement for sustainable lifestyle changes
Putting the evidence side by side Here is the blunt comparison: AOD 9604: 2.6 kg weight loss in 12 weeks (best result), failed six clinical trials, development terminated Semaglutide: 15 to 17 percent body weight loss over 68 weeks, FDA approved, thousands of study participants, consistent results across multiple trials There is no way to frame this comparison that puts AOD 9604 on equal footing with semaglutide when it comes to clinical evidence
Individuals with a known allergy to glutathione or any of its components should avoid this treatment